advertisement

Topcon

Rodríguez-Agirretxe I 9

Showing records 1 to 9 | Display all abstracts from Rodríguez-Agirretxe I

98993 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
Garcia-Medina JJ
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 252-260
98618 Validation of the SITA faster strategy for the management of glaucoma
Rodríguez-Agirretxe I; Loizate E
International Ophthalmology 2022; 42: 2347-2354
98993 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
Benitez-del-Castillo J; Rodríguez-Agirretxe I
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 252-260
98618 Validation of the SITA faster strategy for the management of glaucoma
Astorkiza B; Onaindia A
International Ophthalmology 2022; 42: 2347-2354
98993 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
Lopez-Lopez F
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 252-260
98618 Validation of the SITA faster strategy for the management of glaucoma
Galdos-Olasagasti L
International Ophthalmology 2022; 42: 2347-2354
98993 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
Moreno-Valladares A
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 252-260
98618 Validation of the SITA faster strategy for the management of glaucoma
Basasoro A
International Ophthalmology 2022; 42: 2347-2354
98993 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain

Journal of Ocular Pharmacology and Therapeutics 2022; 38: 252-260

Issue 22-4

Change Issue


advertisement

Oculus